Lactobacillus rhamnosus, LGG® (hereafter referred to by use of the trademark, LGG® ) is the world’s most documented probiotic strain. LGG® has been used worldwide since 1990 as an ingredient in food and dietary supplements with no safety issues.
It has been extensively studied across various health areas, in newborns,1 preterm infants,2 children,3, 4, 5 pregnant women,6, 7 adults8 and in the elderly,9 with no safety issues.
The LGG® strain has been described in more than 250 publications of human studies.
High bile and acid tolerance
Lab-based research has shown that the LGG® strain has high bile and acid tolerance, which may be important for a probiotic strain to survive passage through the gastrointestinal tract and for its potential beneficial effects. (Ref: Data from Chr. Hansen Human Health Development).
The LGG® strain supports intestinal barrier function by helping intestinal integrity and supporting the immune system. (Ref: Data from Chr. Hansen Human Health Development).
Only Chr. Hansen can offer the real LGG®
Chr. Hansen uses state-of-the-art sequencing to generate a closed genome reference sequence of the LGG® probiotic strain. The genome results and sequences have been validated and endorsed by an independent third party. The Valio and Chr. Hansen production strain has remained stable and genomically identical over the last 25 years.
It was observed in 2019 that the ATCC reference deposit of LGG (ATCC53103) was not genomically identical to the Chr. Hansen LGG® production strain or the published LGG sequence.16 For this reason, the LGG® production strain from Chr. Hansen has been deposited at the DSMZ culture collection (DSM33156).
LGG® is safe for human consumption and in Europe has been granted QPS (Qualified Presumption of Safety) status in Europe17 and been the subject of a GRAS (Generally Recognized As Safe) notice to the US Food and Drug Administration,18 with no safety issues.
1 Arvola T, et al. Pediatrics. 1999;104(5):e64.
2 Underwood MA, et al. J Pediatr Gastroenterol Nutr. 2009;48(2):216-25.
3 Vanderhoof JA, et al. The Journal of Pediatrics. 1999;135(5):564-8.
4 Hojsak I, et al. Pediatrics. 2010;125(5):e1171-7.
5 Isolauri E, et al.Pediatrics. 1991;88(1):90-7.
6 Gueimonde M, et al. J Pediatr Gastroenterol Nutr. 2006;42(2):166-70.7. Lahtinen SJ, et al. J Allergy Clin Immunol. 2009;123(2):499-5019. Hatakka K, et al. J Dent Res. 2007;86(2):125-30.
10 Sindhu KNC, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(8):1107-15.
11 Aggarwal S, et al. Indian J Med Res. 2014;139(3):379-85.
12 Hojsak I, et al. Clin Nutr. 2010;29(3):312-6.
13 Nase L, et al. Caries Res. 2001;35(6):412-20.
14 Glavina D, et al. Coll Antropol. 2012;36(1):129-32.
15 Davidson LE, et al. Eur J Clin Nutr. 2011;65(4):501-7.
16 Vos WM. 2009. Proc Natl Acad Sci United States Am 106:17193 –17198.
17 EFSA Panel on Biological Hazards (BIOHAZ). EFSA Journal. 2015;13:4331.
18 Food and Drug Administration. GRAS Notice No GRN 000049. 2002.
LGG® is a registered trademark of Chr. Hansen A/S.
This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.